Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) announced acceptance of long-term clinical data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” for presentation at Digestive Disease Week 2026 (May 2–5, 2026) in Chicago and virtually.

The abstract covers long-term outcomes for a transvascular radiofrequency nerve‑targeted ablation approach intended to reduce severe pain in pancreatic adenocarcinoma patients.

Argus Apr 29 session

-6.66% close to close Open Argus

Details

News Market Reaction – AMIX

On Apr 29, the day this news came out, AMIX closed 6.66% below the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Key Figures

Conference dates: May 2–5, 2026 Net loss: $14.0 million Cash balance: $9.9 million +5 more

Conference dates

May 2–5, 2026

Digestive Disease Week 2026 presentation window

Net loss

$14.0 million

Nine months ended December 31, 2025 (10-Q filed Feb 11, 2026)

Cash balance

$9.9 million

As of December 31, 2025 (10-Q filed Feb 11, 2026)

Additional financing need

$30–$36 million

Estimated to reach first-indication commercialization (10-Q filed Feb 11, 2026)

Lincoln Park facility

$15.0 million

Equity purchase agreement disclosed in 10-Q filed Nov 12, 2025

ATM proceeds

$2.6 million

Fiscal-to-date sales under ATM through Q2 FY2026 (10-Q Nov 12, 2025)

PIPE gross proceeds

$5.0 million

November 2025 private placement warrants financing (8-K Nov 19, 2025)

Warrant exercise potential

$7.7 million

Maximum gross proceeds if Common Warrants fully exercised (S-3 shelf summary)

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Conference presentation

   24h Move

   -2.3%

   Announcement of long-term pancreatic cancer pain data presentation at ECIO 2026.

2. Apr 08

   Conference selection

   24h Move

   +4.5%

   Featured abstract and podium slot for long-term pain mitigation data at SIR 2026.

3. Mar 11

   Investor conference

   24h Move

   +0.3%

   CEO presentation and investor meetings at LSI USA ’26 medtech summit.

4. Mar 05

   Innovation competition

   24h Move

   +2.2%

   Selection for CRT 2026 Best Innovation Competition highlighting nerve-targeted technology.

5. Mar 04

   Top abstract award

   24h Move

   +3.1%

   Top Abstract and podium presentation on transvascular peripheral RF nerve neurolysis at CRT 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pancreatic adenocarcinoma, denervation, transvascular, radiofrequency (rf) energy-based ablation, +4 more

8 terms

pancreatic adenocarcinoma medical

"“Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis..."

Pancreatic adenocarcinoma is a type of cancer that starts in the cells of the pancreas, the organ that helps digestion and controls blood sugar. It matters to investors because it is often aggressive and hard to detect early, so progress or setbacks in diagnostics, drugs or clinical trials can strongly affect the value of companies working on treatments—similar to how a breakthrough or failure in fixing a critical bridge can change the fortunes of contractors and insurers.

denervation medical

"A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation"

Denervation is the loss or deliberate interruption of nerve signals to a specific organ or tissue, often achieved by cutting, destroying, or blocking nerves. Like unplugging a lamp to stop it from turning on, denervation is used as a medical approach to reduce unwanted activity such as high blood pressure or chronic pain; for investors it matters because devices and drugs that perform or affect denervation can drive clinical outcomes, regulatory decisions, safety profiles, and market opportunities.

transvascular medical

"denervation via Transvascular RF Energy-Based Ablation"

Transvascular describes medical procedures, devices or approaches that are performed through the body's blood vessels rather than by open surgery. Think of it like threading a tiny tool through plumbing to reach a problem inside, which often means smaller incisions, faster recovery and different regulatory and reimbursement pathways. Investors watch transvascular products because they can change clinical practice, drive demand for specialized devices and affect approval, adoption and reimbursement risk for healthcare companies.

radiofrequency (rf) energy-based ablation medical

"transvascular radiofrequency (RF) energy-based ablation approach, which is designed"

A medical procedure that uses controlled radiofrequency (RF) electrical energy to heat and destroy targeted tissue, such as tumors, abnormal heart tissue, or problematic nerves. Think of it like a tiny, precise electric heater that burns away unwanted cells without large incisions. Investors care because RF ablation drives demand for specialized devices, affects clinical adoption and reimbursement, and can influence healthcare costs, recurrence rates, and the commercial prospects of device makers and treatment providers.

gastroenterology medical

"global gastroenterology and surgical community."

Gastroenterology is the medical specialty that diagnoses and treats disorders of the digestive system—think of it as the maintenance and repair work for the body’s plumbing, including the esophagus, stomach, intestines, liver, pancreas and gallbladder. It matters to investors because demand for related drugs, devices and diagnostics is driven by how common and costly these conditions are, how new treatments perform in trials, and how insurers reimburse care, all of which affect company revenues and valuations.

hepatology medical

"leaders in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery."

Hepatology is the medical specialty that studies, diagnoses and treats the liver and nearby organs that help process nutrients and remove toxins. For investors, advances, drug trial results or diagnostic breakthroughs in hepatology can change the value of biotech and healthcare companies much like a major engine upgrade can boost a carmaker’s prospects—because successful treatments or tests can open new markets, drive regulatory approvals and affect future revenue.

endoscopy medical

"leaders in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery."

A medical procedure that uses a thin, flexible tube with a tiny camera and small tools to look inside and sometimes treat organs through natural openings or small cuts — like sending a flashlight and repair kit down a pipe to inspect and fix problems. Investors care because the number of procedures, new device designs, safety records, regulatory approvals and reimbursement rules drive sales and profits for hospitals, equipment makers and suppliers.

gastrointestinal medical

"in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery."

Gastrointestinal describes the stomach and intestines and the processes that break down food and absorb nutrients — think of it as the body’s food‑processing and waste‑handling system. For investors, gastrointestinal matters because drugs, devices, or illnesses that affect this system can drive clinical trial outcomes, regulatory decisions, treatment demand and safety concerns, all of which can materially influence revenue, costs and risk for healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), being held May 2–5, 2026, in Chicago, IL and virtually.

Pancreatic adenocarcinoma is frequently associated with severe, debilitating pain that significantly impacts patient quality of life. The data to be presented highlights long-term outcomes associated with Autonomix’s transvascular radiofrequency (RF) energy-based ablation approach, which is designed to target and disrupt nerve signaling pathways responsible for pain transmission.

“This acceptance at DDW 2026 underscores our strategy of socializing and validating our data at preeminent conferences alongside world-renowned KOLs and clinical leaders,” said Dr. Robert Schwartz, Autonomix Co-Founder and Chief Medical Officer. “We are encouraged by the long-term findings and look forward to sharing these insights with the global gastroenterology and surgical community.”

Digestive Disease Week is one of the world’s premier gatherings for physicians, researchers, and industry leaders in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference provides a platform for cutting-edge research and advancements that shape the future of digestive healthcare. For more information, please visit the DDW 2026 conference website here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Autonomix (AMIX) announce for Digestive Disease Week 2026 on April 29, 2026?

Autonomix announced acceptance of long-term clinical data for presentation at DDW 2026. According to the company, the abstract examines long-term outcomes of a transvascular RF energy-based denervation approach for pain mitigation in pancreatic adenocarcinoma patients.

When and where will Autonomix (AMIX) present its pancreatic cancer pain data at DDW 2026?

Autonomix will present at Digestive Disease Week 2026, May 2–5, 2026, in Chicago and virtually. According to the company, the accepted abstract will be shared with the gastroenterology and surgical community during the conference program.

What clinical approach does the Autonomix (AMIX) DDW 2026 abstract describe for pancreatic cancer pain?

The abstract describes a transvascular radiofrequency (RF) energy-based ablation to disrupt nerve signaling for pain relief. According to the company, the analysis reports long-term outcomes associated with that nerve-targeted denervation technique.

How might the DDW 2026 presentation affect Autonomix (AMIX) visibility among clinicians and researchers?

The DDW presentation may increase exposure to gastroenterology and surgical KOLs and researchers. According to the company, acceptance at DDW 2026 helps socialize and validate long-term clinical data with a global medical audience.